Investigational Drug Information for Reparixin
✉ Email this page to a colleague
What is the development status for investigational drug Reparixin?
Reparixin is an investigational drug.
There have been 14 clinical trials for Reparixin.
The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2022.
The most common disease conditions in clinical trials are Breast Neoplasms, Pneumonia, and COVID-19. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, PRA Health Sciences, and Novartis.
Summary for Reparixin
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 202 |
| WIPO Patent Applications | 133 |
| Japanese Patent Applications | 59 |
| Clinical Trial Progress | Phase 3 (2022-03-01) |
| Vendors | 42 |
Recent Clinical Trials for Reparixin
| Title | Sponsor | Phase |
|---|---|---|
| Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Novartis | Phase 2 |
| Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Add-on Reparixin in Adult Patients With ARDS | Dompé Farmaceutici S.p.A | Phase 2 |
Clinical Trial Summary for Reparixin
Top disease conditions for Reparixin
Top clinical trial sponsors for Reparixin
US Patents for Reparixin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
